You are here

Category
Technology Name
Briefcase
Scientist
1621
Novel treatment for angiogenesis-related diseases.Angiogenesis — the growth of new blood vessels from pre-existing vasculature — has an essential role in development, reproduction and repair. Pathological angiogenesis is a common theme in a broad range of diseases such as cancer, autoimmune diseases,...

Novel treatment for angiogenesis-related diseases.Angiogenesis — the growth of new blood vessels from pre-existing vasculature — has an essential role in development, reproduction and repair. Pathological angiogenesis is a common theme in a broad range of diseases such as cancer, autoimmune diseases, age-related macular degeneration and atherosclerosis. The global market for angiogenesis stimulators and inhibitors is forecast to reach ~US $50 billion by the year 2015. Most of the currently marketed angiogenesis regulators, such as Avastin, typically display modest efficacy and therefore further highlight the great need for the development of novel therapeutics. The current technology presents a novel method to treat angiogenesis-related disorders by modulating apolipoprotein B (ApoB).

Applications


  • ApoB is a potential therapeutic target for the treatment of cancer and other non-neoplastic diseases.
  • ApoB levels may serve as a biomarker for cancer metastasis.

Advantages


  • The anti-angiogenic effect of LDL administration was demonstrated in vivo, in zebrafish models, as well as in vitro, in relevant human cells lines.
  • Regulation of ApoB levels may be applied to treat a broad range of angiogenesis-dependent diseases.
  • Detection of ApoB levels can be readily achieved by analysis of body fluids such as blood and plasma.

Technology's Essence


Using a high-throughput genetic screen for vascular defects in zebrafish, researchers at the Weizmann Institute of Science have identified a genetic mutation that leads to excessive angiogenesis. The mutated gene is responsible for the assembly of ApoB-containing lipoproteins such as LDL, otherwise known as the ‘bad’ cholesterol. The group has found that low levels of LDL promote the formation of new blood vessels by directly interacting with the VEGF pathway. The outlined technology offers methods to modulate the levels of ApoB in order to stimulate, or inhibit angiogenesis, dependent on the therapeutic strategy. For example, inhibition of angiogenesis by increasing ApoB levels may repress tumor growth and attenuate its metastatic potential. In another application of this technology, increased circulating levels of ApoB can serve as a biomarker for the overproduction of blood vessels, thus enabling early diagnosis of pathogenic states in angiogenesis-dependent diseases.

+
  • Prof. Karina Yaniv
1441
New protein as a target to treat B cell-related cancer.Chronic lymphocytic leukemia (CLL), a malignant disease characterized by the accumulation of B lymphocytes in the blood, lymphoid organs, and bone marrow, is the second most common type of leukemia in adults, accounting for about 7,000 new cases of...

New protein as a target to treat B cell-related cancer.
Chronic lymphocytic leukemia (CLL), a malignant disease characterized by the accumulation of B lymphocytes in the blood, lymphoid organs, and bone marrow, is the second most common type of leukemia in adults, accounting for about 7,000 new cases of leukemia each year. Presently, there is no cure for CLL, and the overall goal of leukemia treatment is to bring about a remission. Therefore, identifying new proteins that may serve as a target for inducing cell death in the malignant cells is highly desirable. The present technology identifies a new regulator protein that is essential for the survival of CLL cells.

Applications


• Treatment of CLL, as well as other B cell-related cancers (e.g. gastric cancer and renal cell carcinoma), by blocking CD84 activity
• Diagnosis of CLL

Advantages


• Very specific to malignant B cells
• Diagnosis, and therefore treatment, can be made at early stages of the disease

 


Technology's Essence


B cells taken from CLL patients have a high level of the protein CD84. Stimulation of CD84 upregulates the survival of B-CLL. However, inhibition of CD84 activity with a blocking antibody downregulates the expression of another protein which controls B-CLL survival, thus inducing cell death. Therefore, the present invention reveals CD84 as a regulator of B-CLL survival

+
  • Prof. Idit Shachar
1033
A novel diagnostic test to identify individuals with increased risk of lung cancer. Lung cancer is the number one killer among cancers, with 160,000 deaths/year in the USA and 1.6 million/year worldwide. Early detection of lung cancer increases 5-year survival rate from 4% to 54%. Moreover, the...

A novel diagnostic test to identify individuals with increased risk of lung cancer.

Lung cancer is the number one killer among cancers, with 160,000 deaths/year in the USA and 1.6 million/year worldwide. Early detection of lung cancer increases 5-year survival rate from 4% to 54%. Moreover, the National Lung Cancer Trial (NLST) showed that early detection of lung cancer by low-dose CT reduces mortality by at least 20%. Despite recommendations for low-dose CT screening for heavy smokers fulfilling the NLST criteria, compliance is low. In addition, 80 million smokers and ex-smokers in the US who do not fulfil NLST risk criteria have no recommended solution.

The MyRepair test fulfils this unmet medical need by providing a quantitative prediction of lung cancer risk using a simple blood test. The test is based on a personalized measurement of the patient’s DNA repair capacity, a mechanism which is highly connected to the onset of cancer. Therefore, the MyRepair technology can potentially increase early detection of lung cancer and thus save lives.

 

Applications


A novel diagnostic test to identify individuals with increased risk of lung cancer


Advantages


·         Simplicity – MyRepair is based on a simple, cost-effective blood test.

·         Accessibility – Compared to low-dose CT which requires specific equipment, the MyRepair test can be easily integrated in general diagnostic labs and therefore may be more accessible to a larger portion of the population.

·         Additional applications – Since the test is based on measuring personalized DNA repair mechanism, it can be adopted in the future for the diagnosis of additional cancer types and DNA repair related diseases.


Technology's Essence


Based on the strong and well documented connection between impaired capacity for DNA repair and onset of cancer, the Livneh lab invented the MyRepair Test, a method for predicting lung cancer risk, based on measuring activity of 3 DNA repair enzymes.

Combining enzyme activities with experimental risk estimates generated MyRepair Score, which measures personalized DNA repair capacity of tested subjects.

An epidemiological/clinical study performed in Israel, further validated in an independent UK study, demonstrated that lung cancer patients have lower MyRepair Score than healthy people. In addition, subjects who test MyRepair-positive have an 85-fold higher risk to develop lung cancer compared to the general population.

Low MyRepair Score is a risk factor independent of smoking, and of comparable magnitude, indicating that it can be a prognostic tool for smokers, ex-smokers, and non-smokers.

+
  • Prof. Zvi Livneh
1270
Monoclonal antibodies to IgE Description: Rat monoclonal anti-IgE antibodies that was generated by fusion of plasmacytoma (84.1C) or myeloma (EM953) cells with splenocytes of rat immunized with purified murine IgE mAb. The antibodies react with various IgE mAb of different specificities and not with...

Monoclonal antibodies to IgE

Description: Rat monoclonal anti-IgE antibodies that was generated by fusion of plasmacytoma (84.1C) or myeloma (EM953) cells with splenocytes of rat immunized with purified murine IgE mAb. The antibodies react with various IgE mAb of different specificities and not with immunoglobulins of other classes, and recognize an epitope on the murine Fc epsilon region.

Were shown to block IgE-Fc?R interactions and inhibit passive cutaneous anaphylaxis. 

Clone 84.1c recognizes a site on IgE, which is identical or very close to the Fc?R binding site. May be used for detection and manipulation of the IgE response in mice.

Reference:  Schwarzbaum S, Nissim A, Alkalay I, Ghozi MC, Schindler DG, Bergman Y, Eshhar Z. 1989. Mapping of murine IgE epitopes involved in IgE-Fc epsilon receptor interactions. Eur J Immunol 19(6):1015-23.

 

M182, M185, M186

+
  • Prof. Zelig Eshhar
1397
A novel antibody which can be used, for the first time, to recognize ubiquitinated histone 2B. This technology is novel in its ability to recognize proteins and their destinations, and may serve in diagnostics and immunoprecipitation processes.

A novel antibody which can be used, for the first time, to recognize ubiquitinated histone 2B. This technology is novel in its ability to recognize proteins and their destinations, and may serve in diagnostics and immunoprecipitation processes.

Applications


Primary applications in research. Use as a detection tool in western blotting, immunoprecipitation and chromatin immunoprecipitation. Might be used for monitoring processes associated with modulations of ubiquitinated-H2B levels.

Technology's Essence


The invention involves the generation of antibodies specific to ubiquitinated-H2B which selectively recognize H2B when it is ubiquitinated but not H2B in its unmodified state, or ubiquitin unconjugated to H2B.

+
  • Prof. Moshe Oren
1518
Improved immunotherapy for breast cancer. Monoclonal antibodies (mAbs) to ErbB-2/HER2 growth factor receptor, or to its sibling, the epidermal growth factor receptor (EGFR), prolong survival of cancer patients, especially when combined with cytotoxic therapies. However, low effectiveness of...

Improved immunotherapy for breast cancer.

Monoclonal antibodies (mAbs) to ErbB-2/HER2 growth factor receptor, or to its sibling, the epidermal growth factor receptor (EGFR), prolong survival of cancer patients, especially when combined with cytotoxic therapies. However, low effectiveness of therapeutic mAbs and the evolution of patient resistance call for improvements. Furthermore, the response to the clinically approved monotherapy of Herceptin (a humanized mAb directed against ErbB-2), is relatively low (~15%) and short lived (median duration, 9 months). Therefore, there is a need to improve the therapeutic treatment against this receptor. The present technology enhances the therapeutic activity of anti-ErB-2 receptor antibodies, by combining two or more epitope-distinct antibodies.

Applications


  • Improved treatment of ErbB-2-overexpressing tumors (e.g. in breast and ovary cancers).


Advantages


  • May enhance patient response and delay acquisition of resistance.
  • Enhancement of therapeutic efficacy and synergy with chemotherapy.

Technology's Essence


Optimal selection of mAbs for cancer immunotherapy may improve its therapeutic potential. The outlined technology addresses an emerging strategy, which enhances the therapeutic activity of anti-receptor antibodies by combining two mAbs engaging distinct epitopes. It was demonstrated that pairs of anti-ErbB-2 mAbs better inhibit ErbB-2-overexpressing tumors than the respective individual mAbs, both in vitro and in vivo.

+
  • Prof. Yosef Yarden
1245

Applications


The novel DNA Aptamer is a promising candidate for therapeutic as well as diagnostic uses: Therapeutic: A novel therapy for Influenza Diagnostics: Detection of Influenza infection in vertebrates such as avian, swine and human

Technology's Essence


Scientists at the Weizmann Institute of Science describe a novel oligonucleotide, also known as an Aptamer, which has been designed to complement the receptor-binding region of the influenza haemagglutinin molecule. It was constructed by screening a DNA library and processing by the SELEX procedure. This DNA Aptamer comprises of a polynucleotide sequence that can bind to a polypeptide within the binding region of the influenza virus to the host cell. The proposed mode of action of this Aptamer is by blocking the binding of influenza virus to target cell receptors and consequently preventing the virus invasion into the host cells. Aptamer is capable of inhibiting the haemagglutinin capacity of the virus and the viral infectivity in vitro. Furthermore, it was shown in an animal model to inhibit viral infection by different influenza strains, as manifested by up to 99% reduction of virus burden in the lungs of treated mice.

+
  • Prof. Ruth Arnon
1369
A simple, single-step biochip platform for synthesis of biomolecules. Biochip technology is used today in measuring passive probe-target interactions i.e. measurement of the abundance of specific biomolecules). This technology can now be extended to include complex and cascaded activities on the chip...

A simple, single-step biochip platform for synthesis of biomolecules.

Biochip technology is used today in measuring passive probe-target interactions i.e. measurement of the abundance of specific biomolecules). This technology can now be extended to include complex and cascaded activities on the chip. The present immobilization approaches (based on UV photography) have been essentially limited to short single stranded DNA probes and have not been developed for entire genes or other biochemical functions. Furthermore, most biochips are assembled in a multi-step process that requires expertise in surface chemistry in order to obtain reproducibility and robustness. As a result, light-directed immobilization of molecules on biochips is not widespread and is not easily accessible for research and technology development. The present invention enables, in a simple manner, to immobilize different biomolecules anywhere on the chip to submicron resolution through selective exposure of the monolayer to UV light.

 

Applications


  • Light-directed immobilization of a variety of different biomolecules (e.g. DNA, antibodies, enzymes and peptides)
  • On-chip protein biosynthesis from immobilized genes
  • Design and layout of on-chip traps for proteins from crude cell extract
  • Lab-on-a-chip that provides a general use biochip technology

Advantages


  • Enabling the use of long DNA molecules (whole genes)
  • Robust and simple performance without the need for proficiency in materials science and surface chemistry
  • On-chip protein synthesis with high efficiency, minimal non-specific activity, and a wide dynamic range

 


Technology's Essence


This lab-on-a-chip technology (i.e. a technology that enables to perform laboratory operations on a small scale) is based on a newly synthesized molecule termed daisy that combines three parts all-in-one: a tail and head connected by a backbone. Selective exposure of daisy monolayer to UV light through a mask (photolithography) reveals the surface for chemical binding of a variety of biomolecules. Using this technology it is possible to immobilize different biomolecules anywhere on the chip to submicron resolution. By immobilizing whole genes, thus enabling cell-free biosynthesis of proteins, daisy technology takes the lab-on-a-chip concept to the next level. Daisy biochip technology holds a promise in proteomics, diagnostics and therapeutics.

+
  • Prof. Roy Bar-Ziv
1698
GD is an inherited metabolic disorder, affecting about 1 in 20,000 births. GD is divided into three clinical subtypes: type 1 is the most common and is characterized by bruising, fatigue, anemia, low blood platelets, and enlargement of the liver and spleen. Types 2 and 3, also called neuronopathic GD (...

GD is an inherited metabolic disorder, affecting about 1 in 20,000 births. GD is divided into three clinical subtypes: type 1 is the most common and is characterized by bruising, fatigue, anemia, low blood platelets, and enlargement of the liver and spleen. Types 2 and 3, also called neuronopathic GD (nGD), affect 4% of GD patients and additionally include neurological symptoms. Type 1 patients can have a normal life expectancy if treated whereas type 2/3 patients do not survive to reach adulthood. Moreover, GD carriers, approximately 1% of the population, are in a major risk of developing Parkinson’s disease. Current therapies suffer from severe drawbacks in the treatment of type 1 GD and no therapy exists that effectively treat nGD. The present technology offers a novel therapeutic target for the treatment of Gaucher's disease (GD) which addresses also the neurological symptoms.

Applications


  • Alternative treatment for type 1 GD
  • First line therapy for nGD

Advantages


  • A novel therapy for nGD which has no treatment for the present.
  • A novel therapeutic approach for GD type 1, via a previously unknown molecular mechanism.
  • Allows the development of an orally administered treatment, far more convenient for the patients than the existing treatments.
  • Reduced costs compared to the existing therapies of ERP or BMT

Technology's Essence


The proposed technology is based on the discovery that RIP3 is a key player in the manifestation of GD and that inhibiting RIP3 activity is effectively ameliorating the symptoms of GD not only in the less severe type 1 but also in the neuropathic form of the disease, types 2 and 3. nGD is associated with a massive neuronal loss and elevated RIP3 levels. Inhibition of RIP3 in a mouse model of nGD resulted in a dramatic attenuation of disease signs: drastic extension of life span, no weight loss, improvements in motor coordination, reduced neuroinflammation and improved liver and spleen injuries.

+
  • Prof. Anthony H. Futerman
1517
Psychological disorders (e.g. schizophrenia, depression) are among the most prevalent diseases of humankind. These disorders affect approximately 16% of the U.S. population aged 18 and older in a given year, and when less severe conditions are considered as well (e.g. obsessive-compulsive behavior),...

Psychological disorders (e.g. schizophrenia, depression) are among the most prevalent diseases of humankind. These disorders affect approximately 16% of the U.S. population aged 18 and older in a given year, and when less severe conditions are considered as well (e.g. obsessive-compulsive behavior), the percentage is even higher (about 26%). The conventional treatments for such disorders are psychotherapy and nontherapeutic medications. Using these medications however is complicated by side effects and limitations in the amount of time they can be administered.  So far, no disease-modifying therapy has been available for any of these disorders

The present technology, developed by Prof. Michal Schwartz and her team, offers the use of molecules related to a process called sensorimotor gating which is impaired in various psychological disorders. These molecules, such as modified Kisspeptins, can reverse alterations in sensorimotor gating and provide a potential therapeutic to these hard-to-treat conditions.

Applications


•                     Potentially treating various psychological disorders – such as schizophrenia, depression, post-traumatic stress disorder (PTSD), attention deficit disorder, and others.

•                     Possible preventative treatment for the abovementioned disorders.

•                     Novel alternative approach for treating diseases that do not respond well to presently available pharmaceutical agents.


Advantages


 


Technology's Essence


The research group of Prof. Schwartz studied the connection between the immune system and neurological diseases, particularly those that manifest during adolescence. One of the parameters that characterize many such brain disorders is sensorimotor gating, the ability to segregate specific stimuli from the background of constant sensory information. Sensorimotor gating can be measured by a process called PPI (pre-pulse inhibition). PPI is also impaired in immunocompromised mice models, such as immune deficient SCID mice and a model used for schizophrenia studies. The group showed that kisspeptin, the ligand of GPR54 which regulates pubertal development, is involved in the regulation of the sensorimotor gating in vivo. Injection of kisspeptin to SCID mice reversed the abnormal PPI pattern in adults, and can therefore serve as a potential therapy for diseases associated with distorted sensorimotor gating.

+
  • Prof. Michal Eisenbach-Schwartz
1446
Peptide sequences for efficient inhibition of nuclear translocation of proteins. The ability to regulate cellular localization of a biological component is important for many functions such as gene therapy, protection from toxic chemicals, transport of anti-cancer agents, and possibly preventing...

Peptide sequences for efficient inhibition of nuclear translocation of proteins.

The ability to regulate cellular localization of a biological component is important for many functions such as gene therapy, protection from toxic chemicals, transport of anti-cancer agents, and possibly preventing nuclear translocation of oncogenes. To ensure accurate cellular functioning, the spatial distribution of proteins needs to be delicately regulated and coordinated. This is particularly apparent in many signaling proteins that dynamically and rapidly change their localization upon extracellular stimulation. The present invention provides peptides that may be used to regulate the nuclear translocation of proteins that endogenously comprise such nuclear translocation signals.

Applications


  • Inhibition of translocation of endogenous oncogenes and thereby the transcription they induce.

Advantages


  • Regulation of the level of nuclear targeting activity by selection of different amino acids in the peptide sequences.

  • Peptides can be modified in order to make them more stable in the body.
  • Modulation of the nuclear activities of proteins without harming their cytoplasmic activities.

Technology's Essence


The current invention identifies a 3-amino acid domain (Ser-Pro-Ser, SPS), which is a nuclear translocation signal present in signaling proteins such as extracellular signal-regulated kinase (ERK2) protein, SMAD3 and mitogen-activated protein kinase 1 (MEK1). SPS participates in nuclear translocation upon extracellular stimulation. Since several of these proteins are involved in the regulation of cellular proliferation and oncogenic transformation, the SPS domain can compete with the translocation machinery and therefore prevent the translocation of the proteins into the nucleus. As was shown in animal models, inhibiting this mechanism has an advantage over other ways of inhibition as it doesn’t lead to a negative feedback loop which may enhance the production of the protein.

+
  • Prof. Rony Seger
1642
A potential target for anticancer drug design.Cancer is the second leading cause of death in the US, accounting for roughly 23% of all deaths (as of 2008), and with estimated cost of care of $157 billion (as of 2010). Despite major advances in the management of cancer, most types of solid tumors remain...

A potential target for anticancer drug design.
Cancer is the second leading cause of death in the US, accounting for roughly 23% of all deaths (as of 2008), and with estimated cost of care of $157 billion (as of 2010). Despite major advances in the management of cancer, most types of solid tumors remain resistant to conventional treatment modalities. The local microenvironment, or niche, of a cancer cell plays important roles in cancer development. A major component of the niche is the extracellular matrix (ECM), a rich mesh of fibrous proteins surrounding cells that has been shown to exert a protective and supporting effect on cancer progression. Therefore, targeting the ECM represents a novel avenue for rational anticancer drug design. The current technology allows for specific targeting of an enzyme that takes part in ECM assembly and maintenance, and may provide a novel means for combating cancer progression and metastasis emergence.

Applications


  • Inhibitory antibodies to block QSOX1 catalytic activity in ECM as means to combat cancer progression and metastatic disease.
  • ]QSOX1 inhibition may also be utilized to treat lamin-associated disease.

Advantages


  • Since QSOX1 functions outside cells it would be accessible to antibodies that are not readily taken up by cells.
  • Since the microenvironment confers anticancer therapy resistance, a treatment that specifically targets the stromal cells may be synergistically combined with existing therapeutic modalities.

Technology's Essence


A team of researchers at the Weizmann Institute have that a secreted disulfide bond catalyst known as Quiescin sulfhydryl oxidase 1 (QSOX1) is required for proper assembly of the ECM. The main substrates of QSOX1 within the ECM are laminins. Thus, cells lacking QSOX1 show poor incorporation of laminin into the ECM mesh, resulting in decreased cell adherence and perturbed cell migration. Notably, in some cancer types such as pancreatic and breast cancers, QSOX1 and the ECM components it produces are over-expressed. This suggests that modulation of QSOX1 activity may provide a novel means to combating cancer and metastasis. Treatment of cancer cells with a monoclonal QSOX1-targeting antibody effectively blocked cell migration and provides a novel strategy for cancer treatment by QSOX1 inhibition.

+
  • Prof. Deborah Fass

Pages